Recent advances in the management of viral hepatitis

Journal of the Royal College of Physicians of Edinburgh

Volumn 41, Issue 1, 2011, Pages 59-66

  Holt, A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Hepatitis B; Hepatitis c; Liver disease; Nucleos(t)ide analogues; Polymerase inhibitors; Protease inhibitors

Indexed keywords

ALBINTERFERON ALPHA2B; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; DANOPREVIR; ENTECAVIR; LAMIVUDINE; NITAZOXANIDE; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; TARIBAVIRIN; TELAPREVIR; TENOFOVIR; TIBOTEC; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CIRRHOSIS; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; GREAT BRITAIN; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; PATIENT COMPLIANCE;

EID: 79959499366     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2011.113     Document Type: Article

References (42)

1. Hahne S, Ramsay M, Balogun K et al. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol 2004; 29:211-220. doi:10.1016/j.jcv.2003.09.016
2. Cross TJ, Rizzi P, Horner M et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80:277-282. doi:10.1002/jmv.21078
3. World Health Organization. Hepatitis B. Fact sheet No. 204. Geneva: WHO; revised August 2008. Available online at http://www.who.int/mediacentre/factsheets/fs204/en/
4. Fattovich G, Olivari N, Pasino M et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57:84-90. doi:10.1136/gut.2007.128496
5. Lin CL, Liao LY, Liu CJ et al. Hepatitis B genotypes and precore/ basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol 2002; 37:283-287. doi:10.1007/s005350200036
6. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. doi:10.1053/j.gastro.2005.11.016
7. Chan HL, Wong GL, Tse CH et al. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol 2009; 7:1361-1366. doi:10.1016/j.cgh.2009.08.004
8. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
9. Liu S, Zhang H, Gu C et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101:1066-1082. doi:10.1093/jnci/djp180
10. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242. doi:10.1016/j.jhep.2008.10.001
11. Berzigotti A, Abraldes JG, Tandon P et al. Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol 2010; 52:846-853. doi:10.1016/j.jhep.2009.12.031
12. Hansen BE, Buster EH, Steyerberg EW et al. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010; 82:1135-1142. doi:10.1002/jmv.21778
13. Tangkijvanich P, Komolmit P, Mahachai V et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46:117-123. doi:10.1016/j.jcv.2009.07.005
14. Fried MW, Piratvisuth T, Lau GK et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47:428-434. doi:10.1002/hep.22065
15. Lampertico P, Del Ninno E, Vigano M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37:756-763. doi:10.1053/jhep.2003.50148
16. Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886-893. doi:10.1002/hep.23785
17. Papatheodoridis GV, Lampertico P, Manolakopoulos S et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53:348-356. doi:10.1016/j.jhep.2010.02.035
18. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAgpositive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129. doi:10.1016/S0140-6736(05)17701-0
19. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. doi:10.1056/NEJMoa043470
20. Heathcote EJ, Marcellin P, Buti M et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140:132-143. doi:10.1053/j.gastro.2010.10.011
21. Woo G, Tomlinson G, Nishikawa Y et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139:1218-1229. doi:10.1053/j.gastro.2010.06.042
22. Liaw YF, Sheen IS, Lee CM et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 1:62-72. doi:10.1002/hep.23952
23. Jiménez-Pérez M, Saez-Gomez AB, Mongil PL et al. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010; 42:3167-3168. doi:10.1016/j.transproceed.2010.05.127
24. World Health Organization. Global Alert and Response: Hepatitis C. Geneva: WHO; 2002. Available online at http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html
25. Dudley T, O'Donnell K, Haydon G et al Disappointing results of combination therapy for HCV? Gut 2006; 55:1362-1363.
26. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593. doi:10.1056/NEJMoa0808010
27. Page K, Hahn JA, Evans J et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200:1216-1226. doi:10.1086/605947
28. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-456.
29. Liu CH, Liu CJ, Lin CL et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260-1269. doi:10.1086/592579
30. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265-2271. doi:10.1056/NEJMoa032502
31. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401. doi:10.1038/nature08309
32. McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307-2314. doi:10.1053/j.gastro.2010.02.009
33. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801. doi:10.1038/nature08463
34. Muir AJ, Shiffman ML, Zaman A et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52:822-832. doi:10.1002/hep.23743
35. Poordad F, Lawitz E, Shiffman ML et al. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. Hepatology 2010; 52:1208-1215. doi:10.1002/hep.23827
36. Rossignol JF, Kabil SM, El Gohary Y et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide mono-therapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008; 28:574-580. doi:10.1111/j.1365-2036.2008.03781.x
37. Rossignol JF, Elfert A, El Gohary Y et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136:856-862. doi:10.1053/j.gastro.2008.11.037
38. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838. doi:10.1056/NEJMoa0806104
39. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850. doi:10.1056/NEJMoa0807650
40. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-303. doi:10.1056/NEJMoa0908014
41. Tong X, Bogen S, Chase R et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77:177-185. doi:10.1016/j.antiviral.2007.11.010
42. Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475. doi:10.1016/S0140-6736(10)61384-0